PCSK9

Overview

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease and member of the proprotein convertase family, primarily expressed in hepatocytes, intestinal cells, and the kidney. Its canonical role in lipid metabolism centers on the post-translational regulation of the low-density lipoprotein receptor (LDLR): after secretion from the liver, PCSK9 binds directly to LDLR on the hepatocyte surface, promoting its lysosomal degradation rather than receptor recycling. The net consequence is a reduction in hepatic LDL uptake, leading to elevated circulating LDL cholesterol (LDL-C) levels. Gain-of-function mutations in PCSK9 cause autosomal dominant hypercholesterolemia, while loss-of-function variants are associated with lifelong low LDL-C and markedly reduced cardiovascular risk, establishing PCSK9 as one of the most validated therapeutic targets in modern preventive cardiology.

Beyond its classical role in cholesterol homeostasis, PCSK9 has emerged as a pleiotropic regulator with functions extending to vascular biology, immune modulation, and oncology. Pharmacological inhibition of PCSK9 — achieved through monoclonal antibodies, small interfering RNA (siRNA), macrocyclic Peptides, and CRISPR-based gene editing — has become a major research and clinical frontier. The protein's involvement in ferroptosis, antigen presentation, and tumor immune evasion, alongside its well-established role in cardiovascular disease, positions PCSK9 at the intersection of multiple therapeutic domains.

Focus of Latest Publications

Recent publications on PCSK9 have focused heavily on therapeutic inhibition and gene editing as strategies to lower LDL cholesterol and reduce cardiovascular risk. Several studies examined established PCSK9-targeting agents, including evolocumab and alirocumab, as well as inclisiran, a small interfering RNA targeting hepatic PCSK9 messenger RNA. These reports included pooled clinical analyses, randomized trials, and trial designs in diverse populations such as Japanese patients, adolescents with heterozygous familial hypercholesterolaemia, patients with recent acute coronary syndrome, people with HIV infection, and patients without known significant atherosclerosis but with diabetes. Across these studies, PCSK9 inhibition was consistently framed as a means to achieve sustained LDL-C lowering, with some trials specifically evaluating broader cardiovascular outcomes and safety.

A second major theme was the development of new modalities for PCSK9 suppression. One publication described enlicitide (MK-0616), an orally active macrocyclic peptide therapeutic against PCSK9, developed through fragment-based synthetic assembly to address issues in an earlier lead compound and selected for clinical progression after improvements in potency, solubility, stability, and pharmacokinetics. Another study reported laroprovstat as the first oral small-molecule PCSK9 inhibitor, presented in the context of a phase 1 trial in treatment-naïve patients with hypercholesterolemia. In parallel, multiple nanotechnology-based delivery systems were engineered for PCSK9 gene editing, including endogenous-metabolite-inspired polyamine-oleic acid lipid nanoparticles and piperazine-derived diamine lipid nanoparticles. These platforms were used to deliver mRNA or CRISPR/Cas9 cargo, achieving on-target editing at the PCSK9 locus in vivo and sustained reductions in circulating PCSK9 and LDL-C in mouse models, with favorable tolerability reported for the optimized formulations.

Beyond lipid metabolism, recent studies linked PCSK9 to additional disease mechanisms. In abdominal aortic aneurysm, PCSK9 was reported to be enriched in vascular smooth muscle cells, where it promoted ferritinophagy-dependent ferroptosis through changes involving FTH1, NCOA4, LC3-II/I, iron accumulation, lipid peroxidation, and GPX4; pharmacological degradation of PCSK9 with the peptide Cadd4 attenuated aneurysm progression in murine models. Another study used Mendelian randomization to suggest that genetically proxied PCSK9 inhibition may be associated with increased odds of diabetic peripheral neuropathy, although observational NHANES analyses did not show a significant association between statin use and diabetic peripheral neuropathy. PCSK9 was also highlighted in oncology-related work, including a rationale for combining alirocumab with anti-PD-1 therapy in immunorefractory metastatic non-small cell lung cancer, based on preclinical evidence that PCSK9 can act as an immunosuppressive regulator of antigen presentation.

Additional publications explored PCSK9 in proteomic and computational contexts. A pilot proteomics study compared plasma profiles in hypercholesterolemic patients with and without familial hypercholesterolemia treated with PCSK9 inhibitors, while another pooled analysis assessed the clinical efficacy of evolocumab in Japanese patients. A transfer-learning framework for peptide-protein interaction prediction identified PCSK9 among candidate cancer-related targets for snake-venom-derived peptides. Together, these studies show that current PCSK9 research spans established lipid-lowering therapy, emerging oral and RNA-based inhibitors, genome-editing approaches, and mechanistic investigations extending into vascular biology, neuropathy, and cancer immunotherapy.